It has been reported that the overexpression of CEP55 is significantly correlated with tumor staging, aggressiveness and metastasis of many malignant tumors.40 The overexpression of CEP55 has been found in NSCLC, pancreatic cancer, breast cancer and prostate cancer. Here, CEP55 is linked to breast cancer.